EMBC Stock Analysis: Buy, Sell, or Hold?
EMBC - Embecta Corp. Common Stock
$5.23
-0.24 (-4.39%)
▼
5d:
+2.55%
30d:
+60.92%
90d:
+57.53%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 07, 2026
0d
Get Alerted When EMBC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: EMBC shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: EMBC shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$5.10
Based on 0.0% avg growth
INTRINSIC VALUE TODAY
$3.17
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 2.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: EMBC is currently trading at $5.23, which is considered extended relative to its 30-day fair value range of $3.19 to $4.79. The stock's valuation (Forward PE: 3.0) is in line with its historical norms (2.9). At these levels, the market is pricing in 0.4% annual earnings growth.
Technical Outlook: Technically, EMBC is in a strong downtrend. Immediate support is located at $4.20, while resistance sits at $5.62. Short-term momentum is weak, with the stock down 4.4% recently.
Market Sentiment: EMBC scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. However, the stock is trading significantly above the average Wall Street target of $4.00. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, EMBC is in a strong downtrend. Immediate support is located at $4.20, while resistance sits at $5.62. Short-term momentum is weak, with the stock down 4.4% recently.
Market Sentiment: EMBC scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. However, the stock is trading significantly above the average Wall Street target of $4.00. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$3.19 -
$4.79
Company Quality Score
29/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
12.9%
All Signals
- BEARISH: Price extended above range (+9.2% above its trading range)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.4%)
- BEARISH: Trading 23.5% above Wall St target ($4.00)
- BULLISH: Expecting earnings turnaround to 0.4% growth with -8.1% revenue growth
- WARNING: Composite score 29/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.19 -
$4.79
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$4.20
Resistance Level
$5.63
Current Trend
Strong Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
2.97
Wall Street Target
$4.00
(-23.5%)
Revenue Growth (YoY)
-8.1%
Earnings Growth (YoY)
-53.7%
Profit Margin
8.6%
Valuation Premium vs History
+0.4% premium
PE vs Historical
3.0 vs 2.9
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.4%
(market-implied from PE analysis)
1-Year Target
$5.25
(+0%)
2-Year Target
$5.27
(+1%)
3-Year Target
$5.29
(+1%)
3-Yr Target (if PE normalizes)
(PE: 3→3)
PE COMPRESSION
$5.17
(-1%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: -4.0%)
$31.34
(+499%)
Base:
(SPY PE: 3.0, Growth: -4.0%)
$4.63
(-11%)
Bear:
(PE: 2.5, Growth: -4.0%)
$3.94
(-25%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (4x PE), but valuation improves significantly next year (3x PE) as earnings recover.
Trailing PE: 3.72 | Current EPS (TTM): $1.47
Bull Case
$7.21
(+38%)
Analyst growth 19.9%, PE expands to 4.1
Base Case
$6.56
(+25%)
Market implied 19.9%, PE stable at 3.7
Bear Case
$3.72
(-29%)
Severe decline -20.0%, PE contracts to 3.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 22, 2026 2:00 PM ET
Data refreshes hourly during market hours. Next update: 3:00 PM
Data refreshes hourly during market hours. Next update: 3:00 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EMBC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Instruments & Supplies Stocks
Top-rated stocks in Medical Instruments & Supplies by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ISRG
Intuitive Surgical Inc |
BUY
33 analysts |
$478 | 46 HOLD |
|
ALC
Alcon AG |
STRONG BUY
27 analysts |
$86 | 37 SELL |
|
WST
West Pharmaceutical Serv… |
STRONG BUY
13 analysts |
$405 | 66 BUY |
|
RGEN
Repligen Corporation |
STRONG BUY
19 analysts |
$186 | 45 HOLD |
|
RMD
ResMed Inc |
BUY
19 analysts |
$247 | 41 HOLD |
